616 related articles for article (PubMed ID: 29338455)
1. Current treatment options for meningioma.
Apra C; Peyre M; Kalamarides M
Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
[TBL] [Abstract][Full Text] [Related]
2. Clear cell meningiomas: three case reports with genetic characterization and review of the literature.
Ohba S; Sasaki H; Kimura T; Ikeda E; Kawase T
Neurosurgery; 2010 Sep; 67(3):E870-1; discussion E871. PubMed ID: 20683214
[TBL] [Abstract][Full Text] [Related]
3. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
4. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas.
Peyre M; Feuvret L; Sanson M; Navarro S; Boch AL; Loiseau H; Kalamarides M
J Neurooncol; 2017 Jul; 133(3):633-639. PubMed ID: 28536991
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms.
Pham MH; Zada G; Mosich GM; Chen TC; Giannotta SL; Wang K; Mack WJ
Neurosurg Focus; 2011 May; 30(5):E7. PubMed ID: 21529178
[TBL] [Abstract][Full Text] [Related]
6. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
7. New prospects for management and treatment of inoperable and recurrent skull base meningiomas.
Johnson MD; Sade B; Milano MT; Lee JH; Toms SA
J Neurooncol; 2008 Jan; 86(1):109-22. PubMed ID: 17624496
[TBL] [Abstract][Full Text] [Related]
8. Meningioma.
Marosi C; Hassler M; Roessler K; Reni M; Sant M; Mazza E; Vecht C
Crit Rev Oncol Hematol; 2008 Aug; 67(2):153-71. PubMed ID: 18342535
[TBL] [Abstract][Full Text] [Related]
9. The role of radiotherapy in the management of high-grade meningiomas.
Hwang KL; Hwang WL; Bussière MR; Shih HA
Chin Clin Oncol; 2017 Jul; 6(Suppl 1):S5. PubMed ID: 28758409
[TBL] [Abstract][Full Text] [Related]
10. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
Birzu C; Peyre M; Sahm F
Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
[TBL] [Abstract][Full Text] [Related]
11. [Meningiomas: new prognostic factors].
Sanz Esponera J
An R Acad Nac Med (Madr); 2007; 124(2):319-32; discussion 330-2. PubMed ID: 18069599
[TBL] [Abstract][Full Text] [Related]
12. [Meningioma: management of the most common brain tumour].
Hundsberger T; Surbeck W; Hader C; Putora PM; Conen K; Roelcke U
Praxis (Bern 1994); 2016 Apr; 105(8):445-51. PubMed ID: 27078728
[TBL] [Abstract][Full Text] [Related]
13. Survival and Prognostic Predictors of Anaplastic Meningiomas.
Masalha W; Heiland DH; Delev D; Fennell JT; Franco P; Scheiwe C; Mercas BI; Mader I; Schnell O; Grauvogel J
World Neurosurg; 2019 Nov; 131():e321-e328. PubMed ID: 31356972
[TBL] [Abstract][Full Text] [Related]
14. Management of Atypical and Anaplastic Meningiomas.
Buttrick S; Shah AH; Komotar RJ; Ivan ME
Neurosurg Clin N Am; 2016 Apr; 27(2):239-47. PubMed ID: 27012388
[TBL] [Abstract][Full Text] [Related]
15. Biology and clinical management challenges in meningioma.
Mawrin C; Chung C; Preusser M
Am Soc Clin Oncol Educ Book; 2015; ():e106-15. PubMed ID: 25993161
[TBL] [Abstract][Full Text] [Related]
16. Meningiomas: Overview and New Directions in Therapy.
Wang N; Osswald M
Semin Neurol; 2018 Feb; 38(1):112-120. PubMed ID: 29548058
[TBL] [Abstract][Full Text] [Related]
17. High-grade meningiomas: biology and implications.
Bi WL; Prabhu VC; Dunn IF
Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
[TBL] [Abstract][Full Text] [Related]
18. New developments in the pathology of skull base tumors.
Radner H; Katenkamp D; Reifenberger G; Deckert M; Pietsch T; Wiestler OD
Virchows Arch; 2001 Apr; 438(4):321-35. PubMed ID: 11355165
[TBL] [Abstract][Full Text] [Related]
19. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
Martinez NL; Khanna O; Farrell CJ
Chin Clin Oncol; 2020 Dec; 9(6):75. PubMed ID: 32819111
[TBL] [Abstract][Full Text] [Related]
20. Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria.
Pearson BE; Markert JM; Fisher WS; Guthrie BL; Fiveash JB; Palmer CA; Riley K
Neurosurg Focus; 2008; 24(5):E3. PubMed ID: 18447742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
